254 related articles for article (PubMed ID: 26267419)
1. Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment: A 12-Month Naturalistic Cohort Study.
Whale R; Pereira M; Cuthbert S; Fialho R
J Clin Psychopharmacol; 2015 Oct; 35(5):591-5. PubMed ID: 26267419
[TBL] [Abstract][Full Text] [Related]
2. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
Williams W; McKinney C; Martinez L; Benson C
J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
4. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
[TBL] [Abstract][Full Text] [Related]
6. Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area.
Gaviria AM; Franco J; Rico G; Muntané G; Sáez C; Sánchez-Gistau V; de Pablo J; Vilella E
Prim Care Companion CNS Disord; 2017 Mar; 19(2):. PubMed ID: 28346773
[TBL] [Abstract][Full Text] [Related]
7. Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension.
Procyshyn RM; Lamoure JW; Katzman MA; Skinner PL; Sherman SE
J Pharm Pharm Sci; 2019; 22(1):548-566. PubMed ID: 31730504
[TBL] [Abstract][Full Text] [Related]
8. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
Patel R; Chesney E; Taylor M; Taylor D; McGuire P
Psychol Med; 2018 Jul; 48(10):1616-1623. PubMed ID: 29039277
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
[TBL] [Abstract][Full Text] [Related]
10. Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
Kim S; Kim S; Koh M; Choi G; Kim JJ; Paik IH; Kim SH; Choi YS; Lee Y; Suh J; Takeuchi H; Uchida H; Kim E
J Clin Psychiatry; 2021 Jan; 82(1):. PubMed ID: 33434958
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
[TBL] [Abstract][Full Text] [Related]
12. Three-month paliperidone palmitate - a new treatment option for schizophrenia.
Bernardo M; Bioque M
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):899-904. PubMed ID: 27206330
[TBL] [Abstract][Full Text] [Related]
13. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
15. Hospitalizations and economic analysis in psychotic patients with paliperidone palmitate long-acting injection.
Mesones-Peral JE; Gurillo-Muñoz P; Sánchez-Sicilia MP; Miller A; Griñant-Fernández A
Rev Psiquiatr Salud Ment; 2017; 10(1):33-37. PubMed ID: 27053545
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
Cai Q; Patel C; Kim E; Connolly N; Tunceli O; El Khoury AC
Adv Ther; 2019 Apr; 36(4):858-869. PubMed ID: 30848442
[TBL] [Abstract][Full Text] [Related]
18. Factors That Affect Continuation of Antipsychotic Long-Acting Injections.
Taniguchi M; Hatano M; Kamei H; Inagaki R; Yamada S
Biol Pharm Bull; 2019; 42(7):1098-1101. PubMed ID: 31257286
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
Wallman P; Clark I; Taylor D
J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
[TBL] [Abstract][Full Text] [Related]
20. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
